Maze Posts Wider Loss In Q2; Expects Phase 2 CIPheR Data For MZE782 In FY27
(RTTNews) - Maze Therapeutics, Inc. (MAZE) a clinical-stage biotech company, announced financial results for the second quarter, highlighting wider loss than a year ago, driven by higher operating expenses.
Company Profile
Maze is focused on developing small-molecule precision medicines for kidney and metabolic diseases. The company uses its proprietary Maze Compass platform to identify genetically validated disease targets.
Its lead pipeline includes MZE829, an APOL1 inhibitor for APOL1-mediated kidney disease, and MZE782, an SLC6A19 inhibitor being developed for phenylketonuria and chronic kidney disease.
Pipeline Update
MZE829 for APOL1-Mediated Kidney Disease (AMKD)
Maze's oral APOL1 inhibitor MZE829 is being evaluated in the Phase 2 HORIZON trial for AMKD. The company reported positive topline data in March 2026, including a clinically meaningful reduction in proteinuria, and expects updated cohort data in late 2026 or early 2027. The company plans to initiate a pivotal trial in the first half of 2027, subject to regulatory feedback.
MZE782 for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
MZE782 is being evaluated in the Phase 2 CIPheR trial for PKU, with topline data expected in 2027. A Phase 2 proof-of-concept trial in CKD is planned for the first half of 2027 to assess proteinuria reduction.
Q2 2026 Financial Results
For the second quarter ended June 30, 2026, loss was $44.73 million, or $0.76 per share, wider than loss of $33.68 million, or $0.77 per share in the previous year.
Total operating expenses climbed significantly to $48.03 million for the quarter, from $36.48 million a year earlier, primarily due to higher Research and Development, and General and administrative expenditures.
R&D expenses were $34.94 million for the second quarter of 2026, compared to $28.11 million for the same period in 2025. The increase was primarily due to higher costs associated with the advancement of the MZE829 clinical program and increased personnel-related expenses, including non-cash stock-based compensation.
General and administrative costs were $13.09 million, significantly higher than $8.37 million in the prior year, mainly due to higher personnel-related expenses, including non-cash stock-based compensation, and increased professional service costs.
Cash Position
Cash, cash equivalents and marketable securities held by Maze was $494.91 million as of June 30, 2026. The company believes its current cash runway is sufficient to fund operations through the end of 2029.
Business Update
In April 2026, Maze completed a registered offering of common stock and pre-funded warrants, raising approximately $150 million in gross proceeds, before underwriting discounts, commissions and offering expenses.
Stock Quote
MAZE has traded between $12.81 and $53.65 over the last year.
Maze shares are trading up 1.06% at $27.60.
